Glaxosmithkline Pharmaceuticals Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|
| Revenue | 1,005.54 | 981.42 | 1,036.93 |
| Operating Expense | 635.34 | 656.18 | 681.10 |
| Net Profit | 260.14 | 228.58 | 248.69 |
| Net Profit Margin | 25.87 | 23.29 | 23.98 |
| Earning Per Share | 15.35 | 13.49 | 14.45 |
| EBIDTA | 364.78 | 320.52 | 363.28 |
| Effective Tax Rate | 24.13 | 22.46 | 27.39 |
| Particulars | Mar 2025 |
|---|---|
| Revenue | 1005.54 |
| Operating Expense | 635.34 |
| Net Profit | 260.14 |
| Net Profit Margin | 25.87 |
| Earning Per Share | 15.35 |
| EBIDTA | 364.78 |
| Effective Tax Rate | 24.13 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Total Revenue Annual | 3,723.49 | 3,407.25 | 3,216.34 |
| Operating Expenses Annual | 2,554.20 | 2,506.60 | 2,416.92 |
| Operating Profit Annual | 1,316.54 | 880.51 | 903.02 |
| Interest Annual | 1.31 | 1.80 | 1.81 |
| Depreciation | 56.57 | 59.14 | 56.07 |
| Net Profit Annual | 919.05 | 584.69 | 604.71 |
| Tax Annual | 329.39 | 224.35 | 227.69 |
| Particulars | Mar 2025 |
|---|---|
| Total Revenue Annual | 3,723.49 |
| Operating Expenses Annual | 2,554.20 |
| Operating Profit Annual | 1,316.54 |
| Interest Annual | 1.31 |
| Depreciation | 56.57 |
| Net Profit Annual | 919.05 |
| Tax Annual | 329.39 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Cash Flow at the Beginning | 62.15 | 29.74 | 280.79 |
| Cash Flow from Operations | 1,280.03 | 578.94 | 487.94 |
| Cash Flow from Investing | -36.53 | 14.97 | 805.19 |
| Cash Flow from Financing | -769.42 | -561.50 | -1,544.18 |
| Cash Flow at the End | 536.22 | 62.15 | 29.74 |
| Particulars | Mar 2025 |
|---|---|
| Cash Flow at the Beginning | 62.15 |
| Cash Flow from Operations | 1,280.03 |
| Cash Flow from Investing | -36.53 |
| Cash Flow from Financing | -769.42 |
| Cash Flow at the End | 536.22 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| PBDIT Margin (%) | 35.36 | 28.60 | 28.08 |
| PBIT Margin (%) | 33.56 | 26.55 | 26.03 |
| PBT Margin (%) | 7.94 | 11.80 | 11.65 |
| Net PROFIT Margin (%) | 24.68 | 17.16 | 18.90 |
| Return On Networth / Equity (%) | 49.23 | 36.83 | 27.43 |
| Return On Networth /Employed (%) | 58.72 | 44.44 | 33.60 |
| Return On Assets (%) | 43.19 | 28.66 | 24.38 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.01 |
| Asset Turnover Ratio (%) | 1.75 | 1.67 | 1.29 |
| Particulars | Mar 2025 |
|---|---|
| PBDIT Margin (%) | 35.36 |
| PBIT Margin (%) | 33.56 |
| PBT Margin (%) | 7.94 |
| Net PROFIT Margin (%) | 24.68 |
| Return On Networth / Equity (%) | 49.23 |
| Return On Networth /Employed (%) | 58.72 |
| Return On Assets (%) | 43.19 |
| Total Debt / Equity (X) | 0.01 |
| Asset Turnover Ratio (%) | 1.75 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Fixed Assets Annual | 282.87 | 320.36 | 328.90 |
| Total Current Assets Annual | 3,383.55 | 2,765.84 | 2,466.72 |
| Non Current Assets Annual | 717.38 | 781.96 | 860.98 |
| Total Shareholders Funds Annual | 1,949.23 | 1,784.09 | 1,753.00 |
| Total Assets Annual | 4,100.93 | 3,547.80 | 3,327.70 |
| Particulars | Mar 2025 |
|---|---|
| Fixed Assets Annual | 282.87 |
| Total Current Assets Annual | 3,383.55 |
| Non Current Assets Annual | 717.38 |
| Total Shareholders Funds Annual | 1,949.23 |
| Total Assets Annual | 4,100.93 |
EPS (INR)
Expected
15.52
Reported
15.52
Surprise
0.00%
Dec 2024
EPS beaten by 0.00%
Sep 2024
EPS beaten by 0.00%
Jun 2024
EPS beaten by -1.54%
